Synthesis of thrombin-inhibiting heparin mimetics without side effects

@article{Petitou1999SynthesisOT,
  title={Synthesis of thrombin-inhibiting heparin mimetics without side effects},
  author={Maurice Petitou and Jean-P. H{\'e}rault and Andr{\'e} Bernat and Pierre Alexandre Driguez and Philippe Duchaussoy and Jean Claude Lormeau and Jean-M. Herbert},
  journal={Nature},
  year={1999},
  volume={398},
  pages={417-422}
}
Unwanted side effects of pharmacologically active compounds can usually be eliminated by structural modifications. But the complex heterogeneous structure of the polysaccharide heparin has limited this approach to fragmentation, leading to slightly better-tolerated heparin preparations of low molecular mass. Despite this improvement, heparin-induced thrombocytopaenia (HIT), related to an interaction with platelet factor 4 (PF4) and, to a lesser extent, haemorrhages, remain significant side… Expand
Synthesis and Biological Activity of Anticoagulant Heparan Sulfate Glycopolymers
Heparin has been used as an anticoagulant drug for more than 70 years. The global distribution of contaminated heparin in 2007, which resulted in adverse clinical effects and over 100 deaths,Expand
Chemical approaches to define the structure-activity relationship of heparin-like glycosaminoglycans.
TLDR
The minimum heparin binding sequence for FGF1 and FGF2 necessary to promote signaling was investigated and a characteristic pentasaccharide sequence, DEFGH, is required to accelerate the inhibition of thrombin and factor Xa in the blood-coagulation cascade. Expand
Heparin Mimetics: Their Therapeutic Potential
TLDR
The efficacy of low/non-anticoagulant heparin mimetics in animal models of different inflammatory diseases has been demonstrated and clinical data that indicates hepar in has anti-inflammatory activity will raise the momentum for developing heparIn mimetics as a new class of therapeutic agent for inflammatory diseases. Expand
THROMBOSIS AND HEMOSTASIS Binding of anti – platelet factor 4 / heparin antibodies depends on the thermodynamics of conformational changes in platelet factor 4
Heparin, widely used clinically as a parenteral anticoagulant, is a polyanion consisting of iduronic acid, glucuronic acid, and glucosamine residues carrying sulfate groups. Pharmaceutical heparin isExpand
Pharmacokinetics of new synthetic heparin mimetics.
TLDR
The influence of the charge of the oligosaccharides on their pharmacokinetics and underlinest the importance of minimising their non-specific binding to plasma proteins in order to obtain compounds with predictive Pharmacokinetics are shown. Expand
Synthetic heparin derivatives as new anticoagulant drugs.
TLDR
The journey towards a detailed mechanistic understanding of the anticoagulant action of heparin has resulted in synthetic mimetics with improved pharmacodynamic profiles, and novel compounds with both antithrombin III-mediated inhibition of factor Xa and direct thrombin inhibition are emerging. Expand
Cleavage of the antithrombin III binding site in heparin by heparinases and its implication in the generation of low molecular weight heparin.
TLDR
It is shown that glucosamine 3-O sulfation at the reducing end of a glycosidic linkage imparts resistance to heparinase I, II, and III cleavage, and the biological and pharmacological consequences of a heparIn oligosaccharide that contains only a partial AT-III binding site are examined. Expand
Synthetic oligosaccharides as active pharmaceutical ingredients: lessons learned from the full synthesis of one heparin derivative on a large scale.
TLDR
This highlight will focus on the synthesis and the technical challenges associated with the development and the production of complex carbohydrates which will be exemplified with idraparinux and its neutralizable form, idrabiotaparinux. Expand
Heparin mimetics as tools for modulation of biology and therapy
Abstract Heparin, a highly sulfated polysaccharide of the glycosaminoglycan family, has been used as an anticoagulant drug since the 1930s. However, the structural heterogeneity and side effects ofExpand
Comparative effects of two synthetic oligosaccharides on platelet activation induced by plasma from HIT patients
TLDR
The importance of the charge of the polysaccharides in the HIT‐induced platelet reactions measured by diverse methods is demonstrated, of which some are described for this purpose for the first time. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 25 REFERENCES
The Unique Antithrombin III Binding Domain of Heparin: A Lead to New Synthetic Antithrombotics
Heparin, a sulfated glycosaminoglycan, is well known for its anticoagulant effect mediated by the serine protease inhibitor antithrombin III (AT III). Heparin has been used clinically for more thanExpand
Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/ORG 31540).
TLDR
Surprisingly, introduction of O-sulfates in place of N-Sulfates, and methylation of hydroxyl groups, contributes to reinforce the binding to AT III, resulting in an improved pharmacological profile. Expand
Mode of interaction between platelet factor 4 and heparin.
TLDR
Results indicate that the binding of PF4 to heparin occurs by relatively non-specific electrostatic interactions, which may be generally useful in assessing specificity in glycosaminoglycan-protein interactions. Expand
The anticoagulant activation of antithrombin by heparin.
TLDR
A clear definition of the binding site will provide a structural basis for developing heparin analogues that are more specific toward their intended target antithrombin and therefore less likely to exhibit side effects. Expand
Structure and biological activity of heparin.
  • B. Casu
  • Chemistry, Medicine
  • Advances in carbohydrate chemistry and biochemistry
  • 1985
TLDR
The structure and biological activity of heparin are described, being an alternating copolymer of a hexosamine and an alduronic acid, and the repeating disaccharide units constituting the largest fraction of the most common GAG are elaborated in the chapter. Expand
Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4.
TLDR
An octadecasaccharide is therefore the smallest heparin fragment that can accelerate thrombin inhibition by antithrombin III, and was more readily neutralized by platelet factor 4 than were their anti-Factor Xa activities. Expand
The molecular-weight-dependence of the anti-coagulant activity of heparin.
TLDR
It is shown that this probability is a function of the degree of polymerization of heparin, and the relationship between anti-coagulant activity and molecular weight cannot be explained solely on the basis of availability of binding sites for antithrombin. Expand
Studies on a highly active anticoagulant fraction of high molecular weight isolated from porcine sodium heparin.
TLDR
The very highly active HAF fraction, approximately 15% by weight, was eluted at high salt molarity and its anticoagulant activity was congruent to 2-3 times that of PSH as determined by amidolytic as well as clotting methods. Expand
Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa.
TLDR
Results indicate that simultaneous binding of antithrombin and thrombin to high-affinity heparin is a prerequisite to the acceleration of the antithromabin-thrombin reaction and that the minimum heparIn sequence capable of binding both proteins comprises approximately 18 monosaccharide units. Expand
First Synthetic Carbohydrates with the Full Anticoagulant Properties of Heparin.
TLDR
There is evidence that heparin fragments with at least 15 saccharide units are required for thrombin inhibition. Expand
...
1
2
3
...